AT-1727

Modify Date: 2024-01-08 21:08:07

AT-1727 Structure
AT-1727 structure
Common Name AT-1727
CAS Number 74550-97-3 Molecular Weight 452.50
Density 1.326g/cm3 Boiling Point 679.2ºC at 760 mmHg
Molecular Formula C20H32N6O6 Melting Point N/A
MSDS N/A Flash Point 364.6ºC

 Use of AT-1727


Bimolane (AT-1727), a human topoisomerase II inhibitor, can be used as an anti-neoplastic agent and for the research of psoriasis. Bimolane shows leukemogenic activity and induces multiple types of chromosomal aberrations in human lymphocytes[1][2].

 Names

Name 1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]ethyl]piperazine-2,6-dione
Synonym More Synonyms

 AT-1727 Biological Activity

Description Bimolane (AT-1727), a human topoisomerase II inhibitor, can be used as an anti-neoplastic agent and for the research of psoriasis. Bimolane shows leukemogenic activity and induces multiple types of chromosomal aberrations in human lymphocytes[1][2].
Related Catalog
Target

Topoisomerase II

References

[1]. Frantz CE, et, al. Bimolane: in vitro inhibitor of human topoisomerase II. Cancer Lett. 1997 Dec 9;120(2):135-40.

[2]. Roy SK, et, al. Bimolane induces multiple types of chromosomal aberrations in human lymphocytes in vitro. Mutat Res. 2011 Dec 24;726(2):181-7.

 Chemical & Physical Properties

Density 1.326g/cm3
Boiling Point 679.2ºC at 760 mmHg
Molecular Formula C20H32N6O6
Molecular Weight 452.50
Flash Point 364.6ºC
Exact Mass 452.23800
PSA 106.18000
Index of Refraction 1.568

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TL6380300
CHEMICAL NAME :
2,6-Piperazinedione, 4,4'-ethylenebis(1-(morpholinomethyl)-
CAS REGISTRY NUMBER :
74550-97-3
LAST UPDATED :
199612
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C20-H32-N6-O6
MOLECULAR WEIGHT :
452.58
WISWESSER LINE NOTATION :
T6VNV ENTJ B1- AT6N DOTJ& E2- ET6VNV ENTJ B1- AT6N DOTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>1500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
280 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
250 mg/kg/10D-I
TOXIC EFFECTS :
Behavioral - food intake (animal) Blood - changes in leukocyte (WBC) count
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
140 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1400 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - homeostasis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
280 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
37 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
149 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
37200 ug/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
9 mg/kg
SEX/DURATION :
female 7-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
5 mg/kg
REFERENCE :
CYLPDN Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) V.1- 1980- Volume(issue)/page/year: 16,531,1995

 Synonyms

AT-1727
Bimolane
1,2-Bis(4-morpholinomethyl-3,5-dixoxpiperazinyl)ethane
2,6-Piperazinedione,4,4'-ethylenebis(1-(morpholinomethyl)
1,2-Bis(4-morpholinomethyl-3,5-dioxopiperazinyl)-ethane
4,4'-ethane-1,2-diylbis[1-(morpholin-4-ylmethyl)piperazine-2,6-dione]
Top Suppliers:I want be here



Get all suppliers and price by the below link:

AT-1727 suppliers

AT-1727 price